drugset / Trial / NCT06314659

Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months

NCT06314659

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months old.

Timeline

Start
2021-09-17
Primary completion
2024-12-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine Vaccine

Indications

No indication recorded.